FDA Approves Tarlatamab for Extensive-Stage SCLC
The US FDA has granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen) for extensive-stage small cell lung cancer (SCLC) that has progressed after platinum-based chemotherapy. Tarlatamab is a first-in-class bispecific T-cell engager that activates T-cells and targets DLL3-expressing cells. Approval was based on data from the DeLLphi-301 trial, showing an overall response rate of 40% and…